Merck’s stock faced uncertainty due to looming patent expirations for its top-selling drug, causing a decline. However, a recent surge in share price has investors optimistic. With over 40 products in its portfolio, Merck relies heavily on oncology drug Keytruda, set to face patent expiration in 2028, sparking concern.

Despite the patent cliff, Merck’s recent rebound has intrigued investors. Factors like Keytruda Qlex’s approval and promising trial results for Winrevair bolstered confidence. Merck’s acquisition strategy, including Verona Pharma and Cidara Therapeutics, aims to diversify its portfolio and drive future growth.

Investors question if Merck’s recent stock performance is a buying opportunity. The company’s pipeline could yield over $50 billion in annual revenue by the mid-2030s, offsetting Keytruda’s losses. With a history of strategic acquisitions and a focus on innovation, Merck remains a steady, long-term investment option in the pharmaceutical industry.

Read more at Yahoo Finance: Merck’s Stock is Suddenly Soaring, but Is the Struggling Healthcare Giant a Buy?